Just a bag - I understand why shorts and skeptical longs want to dismiss the revelation that a ‘coming soon’ campaign was initiated at SNO because it was just a tote bag. Let me introduce a concept to everyone here who is not a marketer, it is called a marketing channel. Advertisement is released through marketing channels.
Television is obviously a channel
Social media is a channel
A sales force is a channel
Radio is a channel
Newspaper is a channel
Banner ads on conference webpages are a channel
Utilitarian tools used at conferences like key cards, badge laniards, and tote bags ARE A CHANNEL.
A cheap and useful channel that speaks directly to your target audience where as television as an example is incredibly expensive and does not distinguish audience well at all, but still it is a useful channel because that one speaks directly to consumers.
You utilize the channels that will get you the best bang for your buck. Get it, got it, good.
Multiple choice question, which possibility makes the most sense:
A - FDA allows you to market your product before approval at any time as long as you call it a platform technology or use a temporary Brand Name.
B - Avoiding premarket promotion penalties is as easy as dropping the L off the end of your trademarked Branded product name
C - Advertisement only counts if it is on something that I personally deem valuable
D - FDA only allows you to premarket promote using very specific guidelines and only within 6 months of certain approval and does not care what channel you utilize
Now let me ask this question, is it more logical to believe the opinion of the few Biopharmaceutical industry and/or legal members on this board when it comes to interpretation of FDA regulations on ‘coming soon’ campaigns, or a bunch of shorts and beaten down longs who do not have any relevant experience?
The choice is yours to make. I can only help you so much.
BTW as I type this, I am looking at a few banner ads on the screen… is that a worthy channel in your mind or should we dismiss that one too?
